Transgenomic, Inc. Reports Second Quarter 20... (2006. The 2007net loss was comprised of ...)

Transgenomic, Inc. Reports Second Quarter 2007 Results

Date:8/19/2007

2006. The 2007 net loss was comprised of a loss from continuing operations of $1.0 million or $0.02 per share and a gain from discontinued operations of $66,000. The 2007 loss from continuing operations included a $0.9 million gain from the sale of an investment in equity securities and $0.6 million of restructuring charges. The 2006 net loss was comprised of a loss from continuing operations of $0.6 million or $0.01 per share and a loss from discontinued operations of $0.1 million or $0.00 per share.

Net sales from continuing operations were $11.5 million for the six months ended June 30, 2007, compared to $12.7 million during the comparable period of 2006. Gross profit from continuing operations was $6.1 million or 53 percent for the six months ended June 30, 2007 compared to $6.0 million or 48 percent in 2006. Operating expenses from continuing operations were $8.2 million for the six months ended June 30, 2007 compared to $6.7 million during the comparable period of 2006. Cash flows used in operating activities totaled $1.6 million for the six months ended June 30, 2007 compared to cash flows generated in operating activities of $0.7 million used during the same period in 2006.

Comment and Outlook

The Company's President and Chief Executive Officer, Craig Tuttle, noted, "We are very pleased with second quarter net sales. We experienced a substantial improvement over first quarter. Our instrument and consumables revenues met our internal projections and our molecular diagnostics laboratory business grew by more than $200,000 over first quarter. Second quarter net sales in our Pharmaceutical Research Services business were slightly behind our internal projections due to timing issues with receiving samples from some of our key pharmaceutical partners. We believe that we will continue to grow in our research services business and that, combined with our ongoing cost reduction efforts, will support our goal of reaching break even performance by the
'/>"/>

SOURCE Transgenomic, Inc.

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening

Post Your Comments:

(Date:12/15/2009)... Epeius Biotechnologies Corporation, an emerging leader in the ... of the cutting-edge science behind its lead oncology ... world rediscovered the Cyclin G1 gene ... and disease progression, and thus a prime target ... National Cancer Institute investigating the role of microRNAs ...

(Date:12/15/2009)... -- Repligen Corporation (Nasdaq: RGEN ) today ... research funding to support the ongoing development of ... Dystrophy Association (MDA). This grant will support ... GMP manufacture of a drug candidate for human ... only provides important funding for Repligen,s research but ...

(Date:12/15/2009)... NEW YORK, Dec. 15 Reportlinker.com ... is available in its catalogue: ,, ... - Market Forecasts to 2015, Pipeline Analysis ... http://www.reportlinker.com/p0168104/The-Future-of-Orphan-Diseases-Therapeutics---Market-Forecasts-to-2015-Pipeline-Analysis-and-Reimbursement.html ,, Summary ... latest research "The Future of Orphan Diseases ...

(Date:12/15/2009)... CHARLOTTESVILLE, Va., Dec. 15 AstraZeneca ... University of Virginia (UVa) in Charlottesville, today ... strategic research collaboration to enhance development of ... (CAD) with a secondary focus on peripheral ... ) ,, The collaborative preclinical research ...

[0] Scientists Rediscover Gene Target for Cancer Therapy [0] Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program [0] Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement [0] AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease

... race to make solar cells cheaper and more ... on new designs that exploit nanostructures--materials engineered on ... Using nanotechnology, researchers can experiment with and control ... free electrons--properties that are important for the conversion ...

... to CMM for,Professional Services in Finding Genetic Markers ... Jan. 8 The Center for Molecular,Medicine (CMM) ... Children,s,Oncology Group (COG) to provide professional genotyping services ... the existence of genetic,abnormalities and their association with ...

... Jan. 8 Substantial progress and,momentum behind its research-and-development ... deliver several new blockbuster products to farmers,by 2012, company ... part of a series of presentations on the company,s ... to see such innovation in the pipeline right now," ...

Other Biology Technology:New nanostructured thin film shows promise for efficient solar energy conversion 2 New nanostructured thin film shows promise for efficient solar energy conversion 3 Center for Molecular Medicine Selected to Provide DNA Analysis for Children's Oncology Group Leukemia Study 2 Center for Molecular Medicine Selected to Provide DNA Analysis for Children's Oncology Group Leukemia Study 3 Center for Molecular Medicine Selected to Provide DNA Analysis for Children's Oncology Group Leukemia Study 4 Monsanto's R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade 2 Monsanto's R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade 3

New nanostructured thin film shows promise for efficient solar energy conversion Center for Molecular Medicine Selected to Provide DNA Analysis for Children's Oncology Group Leukemia Study Monsanto's R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade

(Date:12/16/2009)... Chu announced today the winners of the 2009 E.O. ... development supporting the Department of Energy and its missions. ... gold medal, a citation and $50,000. Winners ... early next year., "The contributions made by these researchers ... the United States are wide-ranging and meaningful," Secretary Chu ...

(Date:12/16/2009)... determined that short-term, seasonal exposure to pesticides in ... size of wild salmon populations. In addition to ... suggest that exposure to commonly used pesticides may ... populations. , "Major efforts are currently underway ... to recover depressed populations," says David Baldwin of ...

(Date:12/16/2009)... Calif., Dec. 1 GestureTek Inc. ... Release 3.0 - a turnkey, portable, plug ... advertising, exhibits, entertainment and touring promotions. GestureTek ... of patents in camera-enabled gesture recognition technology ... ,, Guaranteed for quality, the CUBE has ...

Breaking Biology News(10 mins):Secretary Chu announces 2009 Ernest Orlando Lawrence Award winners 2 Even at sublethal levels, pesticides may slow the recovery of wild salmon populations 2 GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2 GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 3 Dr Siegals Cookie Diet Book Cracks the Amazon Top 500 60007 1 Dr Siegals Cookie Diet Book Cracks the Amazon Top 500 60007 2 Dr Siegals Cookie Diet Book Cracks the Amazon Top 500 60007 3 Dr Siegals Cookie Diet Book Cracks the Amazon Top 500 60007 4 Pulmo BioTech Inc Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Can 14578 1 Pulmo BioTech Inc Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Can 14578 2 Pulmo BioTech Inc Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Can 14578 3 Pulmo BioTech Inc Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Can 14578 4 Keraderm Closes on 242 5 Million Investment from NewVa Capital Partners LP 5664 1 Keraderm Closes on 242 5 Million Investment from NewVa Capital Partners LP 5664 2 Keraderm Closes on 242 5 Million Investment from NewVa Capital Partners LP 5664 3

[0] Secretary Chu announces 2009 Ernest Orlando Lawrence Award winners [0] Even at sublethal levels, pesticides may slow the recovery of wild salmon populations [0] GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits

... quantifying the role of forests in the carbon ... predictors of forest biomass and carbon flux. Over ... generated testable explanations, derived from physical and biochemical ... However, in two Ecology Letters articles, Helene Muller-Landau ...

... their skeletons using a toothbrush, the Norwegians found one using a ... the North Sea, at an entire 2256 metres below the seabed. ... the time the North Sea wasn't a sea at all, but ... the remains of the old dinosaur now see the light of ...

... may cringe at the idea, but sperm-producing stem cells found ... frozen for future use. A team in the Netherlands has ... inside mouse testes. The hope is that the same thing ... route to help young cancer patients undergoing chemotherapy," Dirk de ...

Other Biology News:Diverse tropical forests defy metabolic ecology models 2 Diverse tropical forests defy metabolic ecology models 3 Diverse tropical forests defy metabolic ecology models 4 Testes to incubate stem cells 2

Diverse tropical forests defy metabolic ecology models The world's deepest dinosaur finding - 2256 metres below the seabed Testes to incubate stem cells

BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....

... used as an internal standard for the ... mass spectrometry. 5-OxoETE is a polyunsaturated keto ... in human neutrophils. It stimulates cytosolic calcium ... 2 nM. 5-OxoETE selectively stimulates the migration ...

... as an internal standard for the quantification ... spectrometry. 5-OxoETE is a polyunsaturated keto acid ... human neutrophils. It stimulates cytosolic calcium levels ... nM. 5-OxoETE selectively stimulates the migration and ...

... These protein size markers are a ... from 16 to 100 kDa. The markers ... SDS-polyacrylamide gels after staining with Coomassie blue. ... Strep•Tag II sequence, the markers can also ...

Biology Products:

BD BioCoat Gelatin 100 mm Culture Dishes from BD Biosciences - Discovery Labware 5-OxoETE-d7, Deuterium Conjugated/Tagged from Cayman Chemical 5-OxoETE-d7, Deuterium Conjugated/Tagged from Cayman Chemical Strep•Tag^® II Perfect Protein™ Markers, 16–100 kDa, Lyophilized from Novagen

Transgenomic, Inc. Reports Second Quarter 20...(2006. The 2007net loss was comprised of ...)